The company’s most durable idea is also its smallest: reach the disease through a vessel, an opening or a pinprick - then turn that procedure into a platform.
URO-1, Inc. is a Greensboro, North Carolina medical device company modernizing the prostate biopsy, a procedure its founder describes as largely unchanged in decades. Founded in 2017 by prostate cancer survivor and serial MedTech entrepreneur Ted Belleza, URO-1 makes the FDA-cleared SUREcore biopsy needle and coreCARE tissue transfer system, a paired platform built to collect larger, more intact tissue cores and preserve their integrity on the way to pathology. The company reports its needle hit 92% targeting accuracy in MRI-ultrasound fusion biopsies versus 36% for conventional needles, and began commercial launch in January 2025 following an $8 million Series A.
Zenflow is a South San Francisco medical device company that built the Spring, a small nitinol coil implanted through a flexible cystoscope to prop open the urethra and relieve the symptoms of an enlarged prostate (benign prostatic hyperplasia). Spun out of Stanford's Biodesign program in 2014, the company won FDA approval in December 2025 for a first-line interventional therapy that requires no catheter afterward, preserves sexual function, and can be reversed. It has raised roughly $85 million across multiple rounds and ran the multinational BREEZE pivotal trial to get there.
Aurie is a Syracuse-based medical device company that built the first FDA-authorized reusable no-touch intermittent catheter system. Founded by industrial designer Souvik Paul after his sister-in-law's catheter-related infections, Aurie reuses a single catheter up to 100 times via a portable Personal Disinfector that cleans, disinfects, and lubricates the device in 36 minutes - cutting waste and recurring costs for people living with neurogenic bladder.
Promaxo builds the world's first single-sided, in-office MRI platform - a compact magnet, AI, and robotics stack that lets urologists run image-guided prostate biopsies and focal treatments in their own clinic, without a hospital scanner suite.